Načítá se...
[(18)F]FDG PET Immunotherapy Radiomics Signature (iRADIOMICS) Predicts Response of Non-small-cell Lung Cancer Patients Treated with Pembrolizumab
BACKGROUND: Immune checkpoint inhibitors have changed the paradigm of cancer treatment; however, non-invasive biomarkers of response are still needed to identify candidates for non-responders. We aimed to investigate whether immunotherapy [(18)F]FDG PET radiomics signature (iRADIOMICS) predicts resp...
Uloženo v:
| Vydáno v: | Radiol Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Sciendo
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7409607/ https://ncbi.nlm.nih.gov/pubmed/32726293 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/raon-2020-0042 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|